Oncimmune Holdings Future Growth

Future criteria checks 2/6

Oncimmune Holdings is forecast to grow earnings and revenue by 120.9% and 105.1% per annum respectively while EPS is expected to grow by 73.5% per annum.

Key information

120.9%

Earnings growth rate

73.5%

EPS growth rate

Biotechs earnings growth	27.8%
Revenue growth rate	105.1%
Future return on equity	n/a
Analyst coverage	Low
Last updated	21 May 2024

Recent future growth updates

Recent updates

Estimating The Intrinsic Value Of Oncimmune Holdings plc (LON:ONC)

Aug 16

Earnings and Revenue Growth Forecasts

AIM:ONC - Analysts future estimates and past financials data (GBP Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
8/31/2025	7	1	2	2	1
8/31/2024	3	-3	-4	-3	1
2/29/2024	1	-3	-6	-5	N/A
11/30/2023	1	-5	-6	-6	N/A
8/31/2023	1	-6	-7	-7	N/A
8/31/2022	3	-9	-6	-5	N/A
5/31/2022	3	-10	-7	-6	N/A
2/28/2022	4	-8	-7	-6	N/A
11/30/2021	3	-7	-7	-5	N/A
8/31/2021	4	-6	-6	-5	N/A
5/31/2021	4	-5	-6	-5	N/A
2/28/2021	3	-5	-6	-6	N/A
11/30/2020	2	-6	-7	-7	N/A
8/31/2020	1	-7	-8	-8	N/A
5/31/2020	1	-8	-9	-9	N/A
2/29/2020	0	-9	-9	-9	N/A
11/30/2019	0	-9	-9	-9	N/A
8/31/2019	0	-9	-8	-8	N/A
5/31/2019	0	-8	-8	-7	N/A
2/28/2019	0	-8	-7	-7	N/A
11/30/2018	0	-7	-7	-7	N/A
8/31/2018	0	-7	-7	-6	N/A
5/31/2018	0	-6	-6	-6	N/A
2/28/2018	0	-6	-6	-6	N/A
11/30/2017	0	-5	N/A	-5	N/A
8/31/2017	0	-5	N/A	-5	N/A
5/31/2017	0	-5	N/A	-4	N/A
2/28/2017	0	-8	N/A	-4	N/A
11/30/2016	0	-10	N/A	-5	N/A
8/31/2016	0	-9	N/A	-4	N/A
5/31/2016	0	-8	N/A	-3	N/A
5/31/2015	1	-2	N/A	-2	N/A
5/31/2014	1	-1	N/A	-2	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ONC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ONC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ONC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ONC's revenue (105.1% per year) is forecast to grow faster than the UK market (3.5% per year).

High Growth Revenue: ONC's revenue (105.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ONC's Return on Equity is forecast to be high in 3 years time

Oncimmune Holdings Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Oncimmune Holdings plc Provides Earnings Guidance for the Year 2024

Oncimmune Holdings plc Provides Earnings Guidance for the Year 2024

Price target increased to UK£2.22

Recent updates

New major risk - Negative shareholders equity

New major risk - Share price stability

Oncimmune Holdings plc to Report First Half, 2024 Results on May 21, 2024

Less than half of directors are independent

Oncimmune Holdings plc Provides Earnings Guidance for the Year 2024

Oncimmune Holdings plc Provides Earnings Guidance for the Year 2024

Full year 2023 earnings released: UK£0.085 loss per share (vs UK£0.13 loss in FY 2022)

New major risk - Share price stability

Oncimmune Holdings plc, Annual General Meeting, Feb 26, 2024

New minor risk - Financial data availability

Oncimmune Holdings plc Announces Board Changes

Less than half of directors are independent

Oncimmune Holdings plc Announces Changes to the Board

Oncimmune Holdings plc Announces Executive Changes

Freenome Holdings, Inc. acquired Oncimmune Limited and Oncimmune Europe GmbH from Oncimmune Holdings plc (AIM:ONC) for £13 million.

Oncimmune Holdings plc, Annual General Meeting, Feb 27, 2023

Oncimmune Holdings plc Announces Appointment of John Goold as Non-Executive Director

Oncimmune Holdings plc has completed a Follow-on Equity Offering in the amount of £2.1 million.

Less than half of directors are independent

Full year 2022 earnings released: UK£0.14 loss per share (vs UK£0.072 loss in FY 2021)

Estimating The Intrinsic Value Of Oncimmune Holdings plc (LON:ONC)

Oncimmune Holdings plc Announces Board Changes

Price target increased to UK£2.22

Less than half of directors are independent

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Oncimmune Holdings Ordinary Shares to Be Deleted from Other OTC

Oncimmune Holdings plc Announces EarlyCDT Lung Test Approved by Ministry of Health for Aragon, Spain

Full year 2021 earnings released: UK£0.072 loss per share (vs UK£0.13 loss in FY 2020)

Oncimmune Holdings plc Announces the Pre-Publication of the First Results from Its Collaboration with Cedars-Sinai Medical Center in Los Angeles

Oncimmune Holdings plc Presents Clinical Abstracts on Melflufen At the 2021 American Society of Clinical Oncology

Oncopeptides AB (publ) Presents New Clinical and Preclinical Melflufen Data At the Upcoming European Hematology Association Meeting

New 90-day high: UK£1.94

First half 2021 earnings released: UK£0.041 loss per share (vs UK£0.083 loss in 1H 2020)

Oncimmune Holdings plc to Report First Half, 2021 Results on Feb 15, 2021

Oncimmune Holdings plc Announces Steps Down of Cheung to as a Non-Executive Director, Effective 19 January 2021

New 90-day high: UK£1.90

Oncimmune Holdings plc Signs Commercial Contracts

Oncimmune Holdings plc, Annual General Meeting, Nov 30, 2020

Annual earnings released: Earnings beat expectations, revenue disappoints

Full year earnings released - UK£0.13 loss per share

Oncimmune Holdings plc to Report Fiscal Year 2020 Results on Oct 30, 2020

New 90-day high: UK£1.73

Oncimmune Holdings plc Initiates U.S. Expanded Access Program with Melflufen in Triple-Class Refractory Multiple Myeloma

Oncimmune Holdings plc announced that it has received £5.25 million in funding from Balderton Capital (UK) LLP and other investors

Oncimmune Holdings plc Signs Collaboration with Genentech

New 90-day high - UK£1.51

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies